India defends generics amid 'vested interests' sullying claims
This article was originally published in Scrip
India's ministry of commerce and industry has swung into damage control mode following an avalanche of media reports that indirectly questioned the quality of Indian medicines against the backdrop of Ranbaxy's settlement of an investigation by the US Department of Justice (DOJ) concerning data integrity and manufacturing processes at two of its domestic sites.
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.